Recombinant lactoferrin - Ventria Bioscience

Drug Profile

Recombinant lactoferrin - Ventria Bioscience

Alternative Names: VEN 100; VEN 101; VEN 120; VEN 130; VEN 140; VEN 150

Latest Information Update: 02 Jan 2017

Price : $50

At a glance

  • Originator Ventria Bioscience
  • Developer Johns Hopkins University; Minneapolis Medical Research Foundation; Rocky Mountain Poison and Drug Center; University of Colorado at Denver; Ventria Bioscience
  • Class Anti-inflammatories; Antibacterials; Antidiarrhoeals; Antineoplastics; Glycoproteins; Iron binding proteins; Recombinant proteins
  • Mechanism of Action Immunomodulators; Macrophage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Inflammation
  • Phase I Inflammatory bowel diseases
  • Discontinued Diarrhoea; Liver failure; Osteoporosis

Most Recent Events

  • 01 Dec 2016 Ventria Bioscience and Minneapolis Medical Research completes a phase II trial in Inflammation (in HIV infected patients) in USA (PO) (NCT01830595)
  • 17 Nov 2016 Johns Hopkins University and Ventria Bioscience plan the phase II ELCIE trial for chronic Inflammation (In the elderly) in USA (PO, capsule) (NCT02968992)
  • 27 Sep 2016 Recombinant lactoferrin (VEN 120) is still in phase I trial for Inflammatory bowel disease in USA (Ventria Bioscience pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top